HK1251179A1 - Car-t细胞的肝动脉灌注 - Google Patents

Car-t细胞的肝动脉灌注 Download PDF

Info

Publication number
HK1251179A1
HK1251179A1 HK18110746.6A HK18110746A HK1251179A1 HK 1251179 A1 HK1251179 A1 HK 1251179A1 HK 18110746 A HK18110746 A HK 18110746A HK 1251179 A1 HK1251179 A1 HK 1251179A1
Authority
HK
Hong Kong
Prior art keywords
cells
car
arterial infusion
hepatic arterial
methods include
Prior art date
Application number
HK18110746.6A
Other languages
English (en)
Chinese (zh)
Inventor
Steven C. Katz
Richard Junghans
Original Assignee
Prospect Chartercare Rwmc Llc D/B/A Roger Williams Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57126310&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1251179(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Prospect Chartercare Rwmc Llc D/B/A Roger Williams Medical Center filed Critical Prospect Chartercare Rwmc Llc D/B/A Roger Williams Medical Center
Publication of HK1251179A1 publication Critical patent/HK1251179A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18110746.6A 2015-04-15 2016-04-14 Car-t细胞的肝动脉灌注 HK1251179A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562147793P 2015-04-15 2015-04-15
US201562147793P 2015-04-15
PCT/US2016/027582 WO2016168493A1 (en) 2015-04-15 2016-04-14 Hepatic arterial infusion of car-t cells

Publications (1)

Publication Number Publication Date
HK1251179A1 true HK1251179A1 (zh) 2019-01-25

Family

ID=57126310

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110746.6A HK1251179A1 (zh) 2015-04-15 2016-04-14 Car-t细胞的肝动脉灌注

Country Status (13)

Country Link
US (2) US10471098B2 (https=)
EP (1) EP3283083A4 (https=)
JP (1) JP2018513216A (https=)
KR (1) KR20180021364A (https=)
CN (1) CN108135937A (https=)
AR (1) AR104296A1 (https=)
AU (1) AU2016248090A1 (https=)
CA (1) CA2982603A1 (https=)
HK (1) HK1251179A1 (https=)
IL (1) IL255005A0 (https=)
MX (1) MX2017013247A (https=)
TW (1) TWI719019B (https=)
WO (1) WO2016168493A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4230262A3 (en) 2015-06-24 2023-11-22 The Regents Of The University Of Michigan Histotripsy therapy systems for the treatment of brain tissue
CN107056952A (zh) * 2017-05-10 2017-08-18 常州市第人民医院 Cea.car‑t及其制备与应用
US20200215112A1 (en) * 2017-08-09 2020-07-09 Ctg Pharma Ltd. Chimeric antigen receptor for her2/neu and t-cells expressing same
CA3080109A1 (en) 2017-11-03 2019-05-09 Sorrento Therapeutics, Inc. Cd38-directed chimeric antigen receptor constructs
ES2982438T3 (es) * 2017-11-30 2024-10-16 Singapore Health Serv Pte Ltd Un sistema y método para clasificar pacientes con cáncer en grupos de tratamiento contra el cáncer adecuados y compuestos para tratar al paciente
AU2019231315A1 (en) * 2018-03-09 2020-09-17 Vivasor, Inc. Dimeric antigen receptors (DAR)
CA3107383A1 (en) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
IL311860A (en) * 2018-08-02 2024-06-01 Kite Pharma Inc Treatment with receptor-antigen chimeric kinetics of T cell expansion and their uses
WO2020046766A1 (en) * 2018-08-26 2020-03-05 Oaiscell Biotechnologies Method for treating glioblastoma
AU2019337603B2 (en) * 2018-09-13 2026-03-05 Nkarta, Inc. Natural killer cell compositions and immunotherapy methods for treating tumors
CN113286552B (zh) 2018-11-28 2025-05-02 希斯托索尼克斯公司 组织摧毁术系统及方法
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
EP3799881A1 (en) 2019-10-04 2021-04-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Single domain antibodies specifically binding globo - series glycans
CA3162755A1 (en) * 2019-11-25 2021-06-03 Kyoto University T-cell master cell bank
WO2021155026A1 (en) * 2020-01-28 2021-08-05 The Regents Of The University Of Michigan Systems and methods for histotripsy immunosensitization
JP2023530477A (ja) 2020-06-18 2023-07-18 ヒストソニックス，インコーポレーテッド 組織破砕音響／患者結合システムおよび方法
EP4204084A4 (en) 2020-08-27 2024-10-09 The Regents Of The University Of Michigan ULTRASONIC TRANSDUCER WITH TRANSMIT-RECEIVE CAPABILITY FOR HISTOTRIPSY
CA3196273A1 (en) * 2020-09-22 2022-03-31 Trisalus Life Sciences, Inc. Cancer therapy using toll-like receptor agonists
CN116685330A (zh) * 2020-09-22 2023-09-01 特萨乐斯生命科学公司 使用toll样受体激动剂的癌症疗法
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
US20240066125A1 (en) * 2021-02-09 2024-02-29 Obi Pharma, Inc. Globo series antigens-binding chimeric antigen receptors and uses thereof
EP4351718A4 (en) 2021-06-07 2025-03-26 The Regents of The University of Michigan MINIMALLY INVASIVE HISTOTRIPSY METHODS AND SYSTEMS
IL308943A (en) 2021-06-07 2024-01-01 Univ Michigan Regents All-inclusive ultrasound systems and methods that include histotripsy
AU2023366591A1 (en) 2022-10-28 2025-04-24 Histosonics, Inc. Histotripsy systems and methods
WO2024221001A2 (en) 2023-04-20 2024-10-24 Histosonics, Inc. Histotripsy systems and associated methods including user interfaces and workflows for treatment planning and therapy
WO2025144964A2 (en) * 2023-12-29 2025-07-03 AffyImmune Therapeutics Inc. Novel car constructs and methods of treatment
WO2026052782A1 (en) 2024-09-06 2026-03-12 Tacalyx Gmbh Anti-globo h antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US20020165360A1 (en) * 2000-11-30 2002-11-07 Junghans Richard P. Chimeric effector cell receptors against carcinoembryonic antigen
WO2010085660A2 (en) * 2009-01-23 2010-07-29 Roger Williams Hospital Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
US9987308B2 (en) * 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
CN103483452B (zh) * 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
CN113684185A (zh) 2013-02-26 2021-11-23 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法

Also Published As

Publication number Publication date
US10471098B2 (en) 2019-11-12
WO2016168493A1 (en) 2016-10-20
EP3283083A1 (en) 2018-02-21
IL255005A0 (en) 2017-12-31
JP2018513216A (ja) 2018-05-24
TW201708542A (zh) 2017-03-01
EP3283083A4 (en) 2018-10-31
MX2017013247A (es) 2018-08-15
US20200138863A1 (en) 2020-05-07
AR104296A1 (es) 2017-07-12
TWI719019B (zh) 2021-02-21
KR20180021364A (ko) 2018-03-02
CN108135937A (zh) 2018-06-08
US20160303166A1 (en) 2016-10-20
AU2016248090A1 (en) 2017-11-02
CA2982603A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
HK1251179A1 (zh) Car-t细胞的肝动脉灌注
MX2023007045A (es) Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos.
MX2020012573A (es) Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b.
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
ZA202007393B (en) Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy
MY195089A (en) Anti-Tim-3 Antibodies and Methods of use thereof
MY199874A (en) Chimeric antigen receptors targeting bcma and methods of use thereof
MY181834A (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
MX420258B (es) Proteínas de unión a nkg2d, cd16 y nectina 4.
PT3268385T (pt) Terapêutica genética combinada de recetores de células t para o cancro, contra epítopos restritos de cph i e cph ii do antigénio de tumor ny-eso-1
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
MY191423A (en) Binding molecules specific for cd73 and uses thereof
MX2017004526A (es) Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.
AU2018253589A1 (en) Antibodies, pharmaceutical compositions and uses thereof
MX2018002315A (es) Anticuerpos anti muerte programada 1 (pd 1) y metodos de uso de los mismos.
HK1247861A1 (zh) 用於癌症治疗的肿瘤周围和肿瘤内部材料
MX2020002036A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor.
NZ732211A (en) Combination immunotherapy approach for treatment of cancer
LT3615066T (lt) Žmogaus antikūnų prieš rankl kompozicijos ir jų panaudojimo būdai
PT3337829T (pt) Método e composição para o tratamento do cancro, matando células cancerosas metastáticas e prevenindo as metástases do cancro usando anticorpos para produtos finais de glicação avançada (pga)
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
EP3271401A4 (en) Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
HK1218860A1 (zh) 卵巢癌疫苗及接种方法
MY186134A (en) Curcumin-peptide conjugates and formulations thereof
IL268744A (en) Methods to enhance tumor immunogenicity and compositions for autologous cancer immunotherapeutic products using modified tumor cells and modified dendritic cells